Señales en vivo de OTLC | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 may 2024 @ 12:37):

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications...

Stats
Volumen de hoy	5 064.00
Volumen promedio	70 993.00
Capitalización de mercado	15.75M
EPS	$0 ( 2024-04-12 )
Próxima fecha de ganancias	( $0 ) 2024-05-17
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.970
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-29	Trieu Vuong	Buy	425 000	Common Stock
2023-06-28	Trieu Vuong	Buy	75 000	Common Stock
2023-06-16	Trieu Vuong	Buy	100 000	Common Stock
2023-06-14	Trieu Vuong	Buy	400 000	Common Stock
2023-05-26	Trieu Vuong	Buy	126 888	Common Stock

INSIDER POWER
100.00
Last 94 transactions
Buy: 129 604 070 \| Sell: 133 128 556

Oncotelic Therapeutics, Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oncotelic Therapeutics, Finanzas

Annual	2023
Ingresos:	$70 000.00
Beneficio Bruto:	$70 000.00 (100.00 %)
EPS:	$-0.0199

FY	2023
Ingresos:	$70 000.00
Beneficio Bruto:	$70 000.00 (100.00 %)
EPS:	$-0.0199

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-12 841.00 (0.00 %)
EPS:	$0.0464

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.0300

Financial Reports:

No articles found.

Oncotelic Therapeutics,

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.